Scotia Capital’s Edesa Biotech EDSA Stock Holding History

Scotia Capital’s Portfolio EDSA Stock Details EDSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$117K	Sell	14,393 -1,450	-9%	-$13.1K	﹤0.01%	883
2026 Q1	$82.9K	Buy	+15,843	New	+$47.5K	﹤0.01%	889

Other funds holding EDSA

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Scotia Capital's EDSA Position: Q2 2026 in Review

Scotia Capital reduced its Edesa Biotech (EDSA) stake by 9.2% in Q2 2026, selling an estimated $13.1K and leaving 14,393 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #883.

Scotia Capital first reported a position in EDSA in Q1 2026 and has held it in 2 quarters since. 30 funds tracked by Wall St. Rank hold EDSA as of Q2 2026.

Scotia Capital held 14,393 shares of Edesa Biotech worth $117K as of Q2 2026.
Scotia Capital sold 1,450 Edesa Biotech shares in Q2 2026, an estimated $13.1K.
Edesa Biotech made up ﹤0.01% of Scotia Capital's portfolio in Q2 2026, its #883 holding.
Scotia Capital first reported a position in Edesa Biotech in Q1 2026 and has held it in 2 quarters since.
30 funds tracked by Wall St. Rank held Edesa Biotech as of Q2 2026.

Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.